NCT06659068View on ClinicalTrials.gov

Efficacy of Seluang Fish Oil (Rasbora Argyrotaenia) and Synbiotics Supplementation on CD4+CD25+ Foxp3+ T-regulator Cells, IL17/IL-10 Ratio, and Disease Activity in Systemic Lupus Erythematosus Patients

NAActive, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 16, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

January 31, 2025

Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
DIETARY_SUPPLEMENT

Seluang fish oil (Rasbora argyrotaenia) and synbiotic

The patients received seluang fish oil (Rasbora argyrotaenia) and synbiotics (containing Lactobacillus helveticus R0052 60%, Bifidobacterium infantis R0033 20%, Bifidobacterium bifidum R0071 20% and frukto-oligosaccharide 80 mg) supplementation

DIETARY_SUPPLEMENT

Placebo

Patients received placebo capsules

Trial Locations (1)

30126

Mohammad Hoesin General Hospital, Palembang

All Listed Sponsors
lead

Universitas Sriwijaya

OTHER

NCT06659068 - Efficacy of Seluang Fish Oil (Rasbora Argyrotaenia) and Synbiotics Supplementation on CD4+CD25+ Foxp3+ T-regulator Cells, IL17/IL-10 Ratio, and Disease Activity in Systemic Lupus Erythematosus Patients | Biotech Hunter | Biotech Hunter